VCEL Vericel

Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million

Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million
EN
14/10/2020

Underlying

VCELVericel

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vericel

 PRESS RELEASE
Free
VCEL VERICEL

Vericel Reports Third Quarter 2025 Financial Results

Vericel Reports Third Quarter 2025 Financial Results Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highli...

November 6, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Report Third-Quarter 2025 Financial Results on November 6, ...

Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025 CAMBRIDGE, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third-quarter 2025 financial results on Thursday, November 6, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at . ...

October 23, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Present at the Wells Fargo Healthcare Conference on Thursda...

Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025 CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Wells Fargo Healthcare Conference at 3:45 p.m. ET on Thursday, September 4, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: . About Vericel Corporation Vericel is a leading p...

August 28, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel Reports Second Quarter 2025 Financial Results

Vericel Reports Second Quarter 2025 Financial Results Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million, with Adjusted EBITDA Margin Increase of More than 900 Basis Points to 21% Approximately 600 MACI Arthro Surgeons Trained to Date Received FDA IND Clearance for Phase 3 MACI Ankle Clinical Study Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a lead...

July 31, 2025 1 EN
 PRESS RELEASE
Free
VCEL VERICEL

Vericel to Report Second-Quarter 2025 Financial Results on July 31, 20...

Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025 CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second-quarter 2025 financial results on Thursday, July 31, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at . Pres...

July 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch